<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781950</url>
  </required_header>
  <id_info>
    <org_study_id>10941-011</org_study_id>
    <nct_id>NCT00781950</nct_id>
  </id_info>
  <brief_title>Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease</brief_title>
  <acronym>FLAXPAD</acronym>
  <official_title>A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Grant Pierce</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Boniface General Hospital Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Clinical Trial is being conducted to study how patients with peripheral arterial disease
      (a condition in which the blood vessels of the extremities are affected) respond to a dietary
      regimen of flaxseed. The purpose of the study is to examine whether or not dietary flaxseed
      have any effect on improving symptoms of cardiovascular disease. Additionally, the effects of
      dietary flaxseed on exercise tolerance will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed trial is a one year, double blinded, placebo controlled study designed to
      examine and compare the effects of dietary ground flaxseed supplementation in volunteers with
      claudication secondary to lower extremity atherosclerotic arterial disease (peripheral
      arterial disease). The original proposal was for a two year study duration but this was
      truncated at one year to insure patient compliance remained high. This patient population is
      likely to benefit from flaxseed because there is a high prevalence of accelerated
      atherosclerosis and a higher than normal incidence of arrhythmias, myocardial infarctions and
      stroke. This study will be focus on whether dietary flaxseed can reduce clinical
      manifestations of peripheral arterial disease and increase exercise capacity in these
      patients. Two general hypotheses will be tested in this proposal. First, we hypothesize that
      fewer primary and secondary events (all-cause mortality, cardiovascular mortality, stroke,
      myocardial infarctions, angina, arrhythmias) will occur in patients who ingest flaxseed in
      their diet. Secondly, we hypothesize that dietary flaxseed supplementation will be associated
      with beneficial effects on exercise performance, blood pressure and circulating lipid levels.
      This trial will generate data on the safety, tolerability, cardiovascular efficacy and
      genomic response to a diet rich in flaxseed in patients with peripheral arterial disease
      (PAD).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on Exercise Performance, Blood Pressure and Circulating Lipid Levels.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flaxseed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flaxseed</intervention_name>
    <description>30 grams of milled flaxseed per day in food products or on its own.</description>
    <arm_group_label>Flaxseed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Wheat and Mixed Dietary Oils</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with peripheral arterial disease for more than 6 months.

          -  Male or female with claudication secondary to lower extremity atherosclerotic arterial
             disease. (with limited IC but not incapacitated for walking on the level) confirmed
             with ankle/brachial pressures&lt; or = to 0.9 in one or both legs) or who have had a
             previous intervention for peripheral arterial disease.

          -  Over 40 years old

          -  Able to comply with protocol requirements

          -  Able to provide informed consent

          -  Subjects taking anti-platelet therapy medication must be on a stable dose for 3 months
             prior to as well as during the study.

          -  Subjects taking lipid lowering medication must be on a stable dose for 3 months prior
             to as well as during the study.

        Exclusion Criteria:

          -  Patients with ischemic rest pain in limbs, ulceration, or gangrene.

          -  At baseline, any condition that prevents walking on a treadmill.

          -  History of major bleeding.

          -  Patients with bowel disease (including Crohn's disease, celiac disease, peptic ulcer
             disease, irritable bowel syndrome and diverticulosis).

          -  Patients with an estimated life expectancy less than 2 years and with high baseline
             cardiac risk (post ischemic or diabetic cardiomyopathy with EF&lt;40%, Canadian
             Cardiovascular Society Class 3 or 4 angina or need for coronary revascularization
             procedures).

          -  Moderate to severe renal failure.

          -  Subjects that are on supplements other that those prescribed by their clinician for
             the entire duration of the study.

          -  Fish limitations (no more than 2 fish meals per week)

          -  Gluten allergy

          -  Subjects with allergies to any ingredient in the study product or placebo.

          -  Patients who plan to undergo surgery during the course of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant Pierce, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <link>
    <url>http://www.sbrc.ca/ccarm</url>
    <description>Canadian Centre for Agri-food Research in Health and Medicine</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <results_first_submitted>December 4, 2014</results_first_submitted>
  <results_first_submitted_qc>December 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2014</results_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Boniface General Hospital Research Centre</investigator_affiliation>
    <investigator_full_name>Dr. Grant Pierce</investigator_full_name>
    <investigator_title>Executive Director, Research Enterprise</investigator_title>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Flax</keyword>
  <keyword>Flaxseeds</keyword>
  <keyword>Functional Foods</keyword>
  <keyword>Essential Fatty Acids</keyword>
  <keyword>Winnipeg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat, wheat bran, and mixed dietary oils to replace the flaxseed daily for one year.</description>
        </group>
        <group group_id="P2">
          <title>Flaxseed</title>
          <description>Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
Flaxseed: 30 grams of milled flaxseed per day in food products or on its own.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat, wheat bran, and mixed dietary oils to replace the flaxseed daily for one year.</description>
        </group>
        <group group_id="B2">
          <title>Flaxseed</title>
          <description>Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
Flaxseed: 30 grams of milled flaxseed per day in food products or on its own.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="9.4"/>
                    <measurement group_id="B2" value="67.4" spread="8.06"/>
                    <measurement group_id="B3" value="67.3" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.</description>
          </group>
          <group group_id="O2">
            <title>Flaxseed</title>
            <description>Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
Flaxseed: 30 grams of milled flaxseed per day in food products or on its own.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Exercise Performance, Blood Pressure and Circulating Lipid Levels.</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat, wheat bran, and mixed dietary oils to replace the flaxseed daily for one year.</description>
          </group>
          <group group_id="O2">
            <title>Flaxseed</title>
            <description>Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
Flaxseed: 30 grams of milled flaxseed per day in food products or on its own.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Exercise Performance, Blood Pressure and Circulating Lipid Levels.</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Final Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.6" spread="3.4"/>
                    <measurement group_id="O2" value="136.2" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" spread="1.5"/>
                    <measurement group_id="O2" value="71.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The adverse events were recorded by the research nurse upon follow-up visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat, wheat bran, and mixed dietary oils to replace the flaxseed daily for one year.</description>
        </group>
        <group group_id="E2">
          <title>Flaxseed</title>
          <description>Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
Flaxseed: 30 grams of milled flaxseed per day in food products or on its own.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Claudication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Iliac Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rest Pain in Limbs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Numbess in Extremities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Grant Pierce</name_or_title>
      <organization>St. Boniface Hospital Research Centre</organization>
      <phone>(204) 235-3414</phone>
      <email>GPierce@sbrc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

